Biostem Technologies Stock Buy Hold or Sell Recommendation
| BSEM Stock | USD 14.44 0.98 6.36% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Biostem Technologies is 'Strong Sell'. The recommendation algorithm takes into account all of Biostem Technologies' available fundamental, technical, and predictive indicators you will find on this site.
Check out Biostem Technologies Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Biostem and provide practical buy, sell, or hold advice based on investors' constraints. Biostem Technologies. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in income.
Biostem |
Execute Biostem Technologies Buy or Sell Advice
The Biostem recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Biostem Technologies. Macroaxis does not own or have any residual interests in Biostem Technologies or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Biostem Technologies' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Biostem Technologies Trading Alerts and Improvement Suggestions
| Biostem Technologies is way too risky over 90 days horizon | |
| Biostem Technologies appears to be risky and price may revert if volatility continues | |
| Biostem Technologies currently holds 1.32 M in liabilities. Biostem Technologies has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biostem Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Biostem Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostem Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostem to invest in growth at high rates of return. When we think about Biostem Technologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 2.52 M. Net Loss for the year was (2.39 M) with profit before overhead, payroll, taxes, and interest of 163.78 K. | |
| Biostem Technologies currently holds about 1.37 M in cash with (581.57 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. | |
| Latest headline from MacroaxisInsider: Acquisition by Seidel-dugan Cynthia of 79516 shares of Werewolf Therapeutics at 11.55 subject to Rule 16b-3 |
Biostem Technologies Returns Distribution Density
The distribution of Biostem Technologies' historical returns is an attempt to chart the uncertainty of Biostem Technologies' future price movements. The chart of the probability distribution of Biostem Technologies daily returns describes the distribution of returns around its average expected value. We use Biostem Technologies price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Biostem Technologies returns is essential to provide solid investment advice for Biostem Technologies.
| Mean Return | 0.82 | Value At Risk | -6.97 | Potential Upside | 12.51 | Standard Deviation | 7.29 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Biostem Technologies historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Biostem Technologies Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Biostem Technologies or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Biostem Technologies' price will be affected by overall otc stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Biostem otc's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.83 | |
β | Beta against Dow Jones | -0.65 | |
σ | Overall volatility | 7.39 | |
Ir | Information ratio | 0.11 |
Biostem Technologies Volatility Alert
Biostem Technologies is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biostem Technologies' otc stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biostem Technologies' otc stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Biostem Technologies Fundamentals Vs Peers
Comparing Biostem Technologies' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Biostem Technologies' direct or indirect competition across all of the common fundamentals between Biostem Technologies and the related equities. This way, we can detect undervalued stocks with similar characteristics as Biostem Technologies or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Biostem Technologies' fundamental indicators could also be used in its relative valuation, which is a method of valuing Biostem Technologies by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Biostem Technologies to competition |
| Fundamentals | Biostem Technologies | Peer Average |
| Return On Equity | -2.21 | -0.31 |
| Return On Asset | -0.6 | -0.14 |
| Operating Margin | (18.22) % | (5.51) % |
| Current Valuation | 37.89 M | 16.62 B |
| Shares Outstanding | 9.24 M | 571.82 M |
| Price To Earning | (0.49) X | 28.72 X |
| Price To Sales | 151.81 X | 11.42 X |
| Revenue | 2.52 M | 9.43 B |
| Gross Profit | 163.78 K | 27.38 B |
| EBITDA | (1.59 M) | 3.9 B |
| Net Income | (2.39 M) | 570.98 M |
| Cash And Equivalents | 1.37 M | 2.7 B |
| Cash Per Share | 0.12 X | 5.01 X |
| Total Debt | 1.32 M | 5.32 B |
| Current Ratio | 0.26 X | 2.16 X |
| Book Value Per Share | (0.26) X | 1.93 K |
| Cash Flow From Operations | (581.57 K) | 971.22 M |
| Earnings Per Share | (0.58) X | 3.12 X |
| Target Price | 6.3 | |
| Number Of Employees | 13 | 18.84 K |
| Beta | 1.56 | -0.15 |
| Market Capitalization | 34.19 M | 19.03 B |
| Total Asset | 2.67 M | 29.47 B |
| Retained Earnings | (5.31 M) | 9.33 B |
| Working Capital | (1.55 M) | 1.48 B |
| Current Asset | 307 K | 9.34 B |
| Current Liabilities | 1.86 M | 7.9 B |
| Z Score | 13.6 | 8.72 |
| Net Asset | 2.67 M |
Biostem Technologies Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Biostem . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Biostem Technologies Buy or Sell Advice
When is the right time to buy or sell Biostem Technologies? Buying financial instruments such as Biostem OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Biostem Technologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Trump Equities Thematic Idea Now
Trump Equities
Stocks that have significantly increased in valuation since Trump was elected president of the United States. The Trump Equities theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Trump Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.